Effect of Urate-lowering Therapy on the Risk of @entity65 and All-cause Mortality in XXXX with Gout: A Case-matched Cohort Study.

@entity1 @entity11368 @entity208 @entity210 @entity204 @entity65
OBJECTIVE: To examine (1) the risk of @entity204 from @entity65 ( @entity65 ) and from all causes in @entity1 with @entity210 who do not undergo urate-lowering therapy (ULT), and (2) the effect of ULT on mortality risk in @entity1 with @entity210 . METHODS: In this prospective case-matched cohort study, 40,623 Taiwanese individuals aged >=  17 years were followed for 6.5 years. Mortality rate was compared between 1189 @entity1 with @entity210 who did not receive ULT and reference subjects (no @entity210 , no ULT) matched for age, sex, and the index date of @entity210 diagnosis (1:3 @entity1 with @entity210 /reference subjects), and between 764 @entity1 with @entity210 who received ULT and 764 @entity1 with @entity210 who did not receive ULT matched 1-to-1 based on their propensity score and the index date of ULT prescription. Cox proportional hazard modeling was used to estimate the respective risk of @entity65 (International Classification of Diseases, 9th ed. code 390-459) and all-cause mortality. RESULTS: After adjustment, @entity1 with @entity210 not treated with ULT had an increased risk of @entity65 mortality (HR 2.43, 95% CI 1.33-4.45) and all-cause mortality (1.45, 1.05-2.00) relative to the matched reference subjects (no @entity210 , no ULT). @entity1 with @entity210 treated with ULT had a lower risk of @entity65 (0.29, 0.11-0.80) and all-cause mortality (0.47, 0.29-0.79) relative to @entity1 with @entity210 not treated with ULT. This survival benefit persisted for users of either @entity208 or @entity11368 . CONCLUSION: @entity1 with @entity210 who received ULT had significantly better survival rates than those who did not. Thus, undertreatment of @entity210 has serious negative consequences.
